Setareh Seyedkazemi, Chief Development Officer at Adverum Biotechnologies, Inc. (ADVM), bought 20,000 shares at $0.84 ($17K) on 2022-05-23, disclosed to the SEC on 2022-05-24.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| ADVM | SELL | 2022-09-21 | $6K | — | Filing → |